Boehringer Ingelheim backs Max Planck spinout in taking a shot at tough class of cancer targets
Scientists have long known about tumor-associated carbohydrate antigens — those abnormal saccharides that are abundant on cancer cell surfaces and feed them on — but their ability to hide from the immune systems means they have proved to be evasive targets in immuno-oncology.
Two glycosciences experts at the Max Planck Institute in Germany believed synthesizing those targets in the first place is key to cracking that problem. They have now received a modest seed round to pursue that idea at their Berlin-based biotech spinout, Tacalyx.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.